MXPA02009437A - Una construccion de acido nucleico que codifica para un componente de procesamiento derivado de la region n-terminal del virus orf2 de hepatits y un polipeptido antigenico. - Google Patents

Una construccion de acido nucleico que codifica para un componente de procesamiento derivado de la region n-terminal del virus orf2 de hepatits y un polipeptido antigenico.

Info

Publication number
MXPA02009437A
MXPA02009437A MXPA02009437A MXPA02009437A MXPA02009437A MX PA02009437 A MXPA02009437 A MX PA02009437A MX PA02009437 A MXPA02009437 A MX PA02009437A MX PA02009437 A MXPA02009437 A MX PA02009437A MX PA02009437 A MXPA02009437 A MX PA02009437A
Authority
MX
Mexico
Prior art keywords
nucleic acid
processing
processing component
seq
protein
Prior art date
Application number
MXPA02009437A
Other languages
English (en)
Spanish (es)
Inventor
Damian Francis John Purcell
Original Assignee
Nd Public Health Ltd Macfarlan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nd Public Health Ltd Macfarlan filed Critical Nd Public Health Ltd Macfarlan
Publication of MXPA02009437A publication Critical patent/MXPA02009437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA02009437A 2000-03-31 2001-03-30 Una construccion de acido nucleico que codifica para un componente de procesamiento derivado de la region n-terminal del virus orf2 de hepatits y un polipeptido antigenico. MXPA02009437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ6616A AUPQ661600A0 (en) 2000-03-31 2000-03-31 A nucleic acid construct and methods related thereto
PCT/AU2001/000353 WO2001073078A1 (en) 2000-03-31 2001-03-30 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide

Publications (1)

Publication Number Publication Date
MXPA02009437A true MXPA02009437A (es) 2006-05-25

Family

ID=3820712

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009437A MXPA02009437A (es) 2000-03-31 2001-03-30 Una construccion de acido nucleico que codifica para un componente de procesamiento derivado de la region n-terminal del virus orf2 de hepatits y un polipeptido antigenico.

Country Status (14)

Country Link
US (1) US7341723B2 (enExample)
EP (1) EP1274851B1 (enExample)
JP (1) JP2003528614A (enExample)
KR (1) KR100768051B1 (enExample)
CN (1) CN1426472A (enExample)
AT (1) ATE430804T1 (enExample)
AU (1) AUPQ661600A0 (enExample)
CA (1) CA2407036A1 (enExample)
DE (1) DE60138612D1 (enExample)
HK (1) HK1052368A1 (enExample)
MX (1) MXPA02009437A (enExample)
NZ (1) NZ521758A (enExample)
WO (1) WO2001073078A1 (enExample)
ZA (1) ZA200207769B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004761A2 (en) 2002-07-05 2004-01-15 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
KR100641810B1 (ko) * 2004-04-23 2006-11-06 주식회사 포스코건설 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
EP2400982B1 (en) * 2009-02-27 2016-05-11 The Regents of The University of California Multiple antigen delivery system using hepatitis e virus-like particle
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle

Also Published As

Publication number Publication date
US7341723B2 (en) 2008-03-11
EP1274851B1 (en) 2009-05-06
EP1274851A1 (en) 2003-01-15
WO2001073078A1 (en) 2001-10-04
EP1274851A4 (en) 2004-12-08
HK1052368A1 (zh) 2003-09-11
DE60138612D1 (de) 2009-06-18
KR100768051B1 (ko) 2007-10-18
ATE430804T1 (de) 2009-05-15
KR20030015223A (ko) 2003-02-20
AUPQ661600A0 (en) 2000-05-04
CA2407036A1 (en) 2001-10-04
CN1426472A (zh) 2003-06-25
US20030158138A1 (en) 2003-08-21
ZA200207769B (en) 2004-02-10
JP2003528614A (ja) 2003-09-30
NZ521758A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
AU2018232999B2 (en) Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
JP7083362B2 (ja) セネカウイルスａ免疫原性組成物およびその方法
Van Rooij et al. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs
KR20210092762A (ko) 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물
JP2004313196A (ja) コロナウイルスに対するワクチン接種用組成物および方法
EP4410843A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
EP2057268B1 (en) A dna vaccine for curing chronic hepatitis b and a method of preparing same
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US20150252084A1 (en) Compositions and methods that enhance an immune response
KR20230005265A (ko) Sars-cov-2에 대한 백신 및 이의 제조
CN1650013A (zh) 抗汉坦病毒属病毒感染的dna疫苗
US7341723B2 (en) Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
EP0614979B1 (en) Hog cholera virus vaccine and diagnostic
JP2010279361A (ja) Ｈｉｖ抗原およびサイトカインをコードする禽痘ベクター
JPH10503649A (ja) ポリヌクレオチド・ヘルペスウイルス・ワクチン
AU2001243941B2 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
AU2001243941A1 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
MXPA01010481A (es) Acidos nucleicos y polipeptidos de lisavirus quimerico.
KR20110060865A (ko) 리슈마니아증 및 결핵에 대한 백신 개발을 위한 ｄｎａ 키메라의 작제
US20040254365A1 (en) Immunization against flavivirus
US20160215023A1 (en) Simple vaccines from dna launched suicidal flaviviruses
HK40010429B (en) Rift valley fever virus glycoproteins, gn and gc, and their use
CN114315985A (zh) 减毒猪流行性腹泻病毒
HK40010429A (en) Rift valley fever virus glycoproteins, gn and gc, and their use
KR19980032276A (ko) 서울 바이러스 r22의 뉴클레오캡시드 단백질 유전자, 재조합 플라스미드, 형질전환 대장균, 및 신증후 출혈열 진단제 및 예방백신

Legal Events

Date Code Title Description
HC Change of company name or juridical status